S&P 500   3,382.91 (+0.08%)
DOW   27,938.98 (-0.14%)
QQQ   274.17 (+0.85%)
AAPL   461.35 (+2.06%)
MSFT   210.64 (+0.69%)
FB   263.17 (+1.26%)
GOOGL   1,524.50 (+1.15%)
AMZN   3,201.53 (+1.24%)
NVDA   461.65 (+0.88%)
CGC   17.32 (+0.41%)
BABA   253.87 (-0.52%)
TSLA   1,636.85 (+5.28%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.10 (-1.07%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,382.91 (+0.08%)
DOW   27,938.98 (-0.14%)
QQQ   274.17 (+0.85%)
AAPL   461.35 (+2.06%)
MSFT   210.64 (+0.69%)
FB   263.17 (+1.26%)
GOOGL   1,524.50 (+1.15%)
AMZN   3,201.53 (+1.24%)
NVDA   461.65 (+0.88%)
CGC   17.32 (+0.41%)
BABA   253.87 (-0.52%)
TSLA   1,636.85 (+5.28%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.10 (-1.07%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,382.91 (+0.08%)
DOW   27,938.98 (-0.14%)
QQQ   274.17 (+0.85%)
AAPL   461.35 (+2.06%)
MSFT   210.64 (+0.69%)
FB   263.17 (+1.26%)
GOOGL   1,524.50 (+1.15%)
AMZN   3,201.53 (+1.24%)
NVDA   461.65 (+0.88%)
CGC   17.32 (+0.41%)
BABA   253.87 (-0.52%)
TSLA   1,636.85 (+5.28%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.10 (-1.07%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,382.91 (+0.08%)
DOW   27,938.98 (-0.14%)
QQQ   274.17 (+0.85%)
AAPL   461.35 (+2.06%)
MSFT   210.64 (+0.69%)
FB   263.17 (+1.26%)
GOOGL   1,524.50 (+1.15%)
AMZN   3,201.53 (+1.24%)
NVDA   461.65 (+0.88%)
CGC   17.32 (+0.41%)
BABA   253.87 (-0.52%)
TSLA   1,636.85 (+5.28%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.10 (-1.07%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
Log in

Walgreens (NASDAQ: WBA) vs CVS (NYSE: CVS): Both Are A Value But There’s Only One I Want To Buy

Posted on Friday, July 10th, 2020 by Thomas Hughes

Walgreens (NASDAQ: WBA) vs CVS (NYSE: CVS) :Both Are A Value But There’s Only One I Want To BuyA Tale Of Two Drug-Stores

Neither CVS Health Corporation (NYSE: CVS) nor Walgreens Boots Alliance (NASDAQ: WBA) has staged much of a rebound in the post-pandemic world. This is surprising given their status as the largest retailers of staple, consumer-oriented, healthcare products in the post-pandemic world. At today’s prices, both present deep-values for dividend investors but only one stands out as a buy. At least, if you can only buy one, one of them is the clear winner for investment today.

The Dividends: Market-Beating Yield, And Growth Too!

  • CVS is not a Dividend King or even a Dividend Aristocrat but it does have a solid history of past increases. In fact, until just a few years ago, the company had increased its payment for 20 years. The stock is yielding about 3.25% which is closing in on double the broad market average. In terms of safety, the payout ratio is a low 28% of earnings and backed up by a near-fortress balance sheet. Debt is low, cash is ample, and coverage is high. No sign of a suspension or cut in these cards.
  • Walgreens is a Dividend Aristocrat verging on Kingship with 44 years of consecutive annual increases. The 5-year CAGR is a bit lower than that of CVS but offset by a higher expectation of increases and a much better yield. At today’s prices, 13-year lows, this stock is yielding closing to 4.75% with an equally strong balance sheet. The payout ratio is running in the mid-30% range with equally good coverage and debt ratios.

The Earnings Outlook:

  • CVS is expected to post slightly positive revenue and earnings growth in 2020. This will be compounded by an acceleration of growth in 2021 that puts the two-year growth rate (from the pre-COVID through the post-COVID period) at roughly 6% earnings and 6.5% revenue. The analysts are generally bullish on the stock and have been inching their targets and ratings up over the past three months.
  • Walgreens is expected to post steady low-single-digit revenue growth this year and next. The negative in the outlook is that this year’s -12% decline in EPS will not be offset by next year’s 17% rebound. The two-year outlook for growth has consensus for revenue at 4.75% and eps at -7.50%. What is perhaps the mitigating factor is that the two company’s fiscal’s years are not directly comparable. CVS reports 4th quarter earnings in December while Walgreens will do the same next month. In that light, the outlook for Walgreens is robust EPS growth in the range of 12% during the period starting now while CVS’ will be a bit more tepid in the 5% range.
Walgreens (NASDAQ: WBA) vs CVS (NYSE: CVS) :Both Are A Value But There’s Only One I Want To Buy

The Valuations Are Compelling

At face value, both stocks are a deep discount to their average broad-market cousins. Trading in the 7X to 9X forward earnings range these stocks are roughly a third the value of the average S&P stock and at long-term lows compared to their historic averages. The difference is that CVS is trading in the 8-9 range while Walgreens is in the 7-8 range and trading at its long-term lows. CVS is sitting a bit off of its lows suggesting that it will either move down to match WBA or vice versa.

On a technical basis, I prefer Walgreens because it is sitting on potentially very strong support while CVS looks like it may retreat. Add to this the fact of Walgreens’ superior yield, equally strong balance sheet, positive outlook for growth in the current period, and lower valuation and it becomes the winner in my book. If you’re looking for a high-growth rebound play that is lagging the broad market this could be the ticket.

Walgreens (NASDAQ: WBA) vs CVS (NYSE: CVS) :Both Are A Value But There’s Only One I Want To Buy

Companies Mentioned in This Article

CompanyBeat the Market™ RankCurrent PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
CVS Health (CVS)2.4$64.31-1.0%3.11%10.22Buy$82.13
Compare These Stocks  Add These Stocks to My Watchlist 

8 Stocks Beaten Down by the Coronavirus That Are Too Good to Pass Up

The coronavirus crash has not discriminated in its victims. Large-cap, mid-cap, and small-cap stocks have all been dropping. No sector has been spared either. And while the market flipped from a bear market to a bull market in just three days, there’s still plenty of volatility to cause cautious investors to keep a healthy social distance from many stocks.

The pandemic that is forcing most of us to stay in our homes as much as possible (and if you’re not, please do) is unique for most of us. Demand hasn’t organically diminished. It’s been artificially suppressed. And that means that while it’s fair to say our economy will certainly experience a new normal, there will be a recovery.

And when it comes, many of the companies that were strong before the pandemic broke will continue to show their strength. Investors who are investing in these companies today will be the ones that experience the greatest gains when the recovery happens.

View the "8 Stocks Beaten Down by the Coronavirus That Are Too Good to Pass Up".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.